Venture capital is flowing back into biotech, but not everyone is sharing in the recovery.
According to BioPharma Dive, funding totals for the first half of the year represented the highest first-half sum since the start of 2022. On its face, that marks a strong rebound in venture capital investment for an industry that has spent recent years navigating a fundraising slump.
But the headline numbers hide a widening divide. BioPharma Dive reports that industry watchers are concerned small startups are being left behind, even as the overall totals climb. In other words, the rebound appears to be concentrated, with larger or later-stage companies capturing much of the renewed enthusiasm while smaller, earlier-stage firms struggle to attract backing.
That gap matters because early-stage biotech startups are often where the riskiest and most novel science gets its first shot at funding. Many of tomorrow's treatments begin at exactly the kind of small companies that industry observers now worry are being squeezed out. A recovery that rewards established players but starves newcomers could narrow the pipeline of experimental medicines over the longer term.
The dynamic also reflects a broader caution among investors. A rebound in total dollars can coexist with a flight to safety, where capital clusters around perceived winners rather than spreading across a wide field of unproven ideas.
Why it matters: if biotech's funding recovery keeps concentrating money at the top, the small startups that seed future breakthroughs may find the door closing just as the industry appears to be reopening.